Deepcell Launches REM-I OnSite, Bringing Fully On-Premises Single Cell Analysis to Regulated and Data-Sensitive Environments
New version of Axon Software enables complete run management, analysis, and visualization on-device, keeping all data local, sovereign, and air-gapped
MENLO PARK, CA, April 21, 2026 — Deepcell, a pioneer in AI-powered, label-free single cell analysis and sorting, today announced the launch of REM-I OnSite, a new deployment configuration of its Axon Data Suite software that runs entirely on the REM-I instrument, with no cloud dependency required.
REM-I OnSite enables the full Axon software experience, including run management, morphological analysis, and data visualization, to operate locally on the instrument. All data remains on-device and fully air-gapped, giving institutions complete control over their research data without routing it through external infrastructure.
The capability is designed for environments where data sovereignty is a non-negotiable requirement including large pharmaceutical organizations with stringent data governance policies, GxP-regulated facilities, and international placements where use of Western cloud infrastructure is restricted or prohibited.
"As we expand REM-I into the world's most sophisticated research organizations, we recognize that cloud connectivity is not always an option for our customers." said Maddison Masaeli, PhD, Co-founder and CEO of Deepcell. "REM-I OnSite means we can bring the full power of AI-driven morphology profiling to any environment, on any terms the customer requires."
For Deepcell's international commercial expansion, including placements in China and other markets with data localization requirements, REM-I OnSite removes a key adoption barrier by ensuring that no research data leaves the customer's facility.
"Data generated on the REM-I is some of the most sensitive and competitively valuable data our customers produce," said Mahyar Salek, Co-founder and CTO of Deepcell. "REM-I OnSite was built so that data never has to leave the room it was created in. For our pharma partners and international customers alike, that is not a feature; it is a requirement."
REM-I OnSite is available as a deployment option for new and existing REM-I customers. Deepcell's commercial team works with each institution to configure the appropriate deployment model based on their infrastructure and compliance needs.
About Deepcell Deepcell is a life sciences company pioneering AI-powered, label-free single cell morphology profiling and sorting. Its REM-I platform enables researchers to capture, analyze, and isolate cells based on high-dimensional morphological features; unlocking new biological insights and driving innovation across oncology, cell therapy, immunology, and ophthalmology. Deepcell's platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions, helping power basic and translational research and offering future applications in diagnostic testing and therapeutic targeting. The company was spun out of Stanford University in 2017 and is based in Menlo Park, California. Learn more at www.deepcell.com.
Contact: Deepcell, Inc. info@deepcellbio.com